𝔖 Bobbio Scriptorium
✦   LIBER   ✦

NIHRAC and FDA ponder gene-therapy risks

✍ Scribed by Fox, Jeffrey L.

Book ID
109901216
Publisher
Nature Publishing Group
Year
1993
Tongue
English
Weight
227 KB
Volume
11
Category
Article
ISSN
1087-0156

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

NIH and FDA size gene therapy
NIH and FDA size gene therapy
πŸ“‚ Article πŸ“… 1994 πŸ› Springer Science and Business Media LLC 🌐 English βš– 303 KB
Gene therapy strategies for hemophilia:
Gene therapy strategies for hemophilia: benefits versus risks
✍ Inge Petrus; Marinee Chuah; Thierry VandenDriessche πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 167 KB

## Abstract Hemophilia is an inherited bleeding disorder caused by a deficiency of functional clotting factors VIII or IX in the blood plasma. The drawbacks of the classical protein substitution therapy fueled interest in alternative treatments by gene therapy. Hemophilia has been recognized as an